PARP1 and glioblastoma: [183] demonstrated that reduced DDR capacity through PARP1 inhibition (olaparib) in conjunction with epigenetic‐downregulation‐induced oxidative stress through histone deacetylase (HDAC) inhibition (vorinostat) led to reduced glioblastoma cell survival, induced apoptosis and impaired cell cycle progression.